Modifying factors of PD‐L1 expression on tumor cells in advanced non‐small‐cell lung cancer

BACKGROUND: Programmed death ligand‐1 (PD‐L1) expression predicts immunotherapy utility in nononcogenic addictive lung adenocarcinoma (ADC). However, its reproducibility and reliability may be compromised outside clinical trials. This study aimed to evaluate factors associated with PD‐L1 expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Avilés‐Salas, Alejandro, Flores‐Estrada, Diana, Lara‐Mejía, Luis, Catalán, Rodrigo, Cruz‐Rico, Graciela, Orozco‐Morales, Mario, Heredia, David, Bolaño‐Guerra, Laura, Soberanis‐Piña, Pamela Denisse, Varela‐Santoyo, Edgar, Cardona, Andrés F., Arrieta, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715877/
https://www.ncbi.nlm.nih.gov/pubmed/36317227
http://dx.doi.org/10.1111/1759-7714.14695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715877/
https://www.ncbi.nlm.nih.gov/pubmed/36317227
http://dx.doi.org/10.1111/1759-7714.14695

Ejemplares similares